Clinical trial
Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and…
NCT00147160 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Completed
Key facts
| NCT number | NCT00147160 |
|---|---|
| Title | Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents |
| Official title | Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioma |
| Intervention type | Drug |
| Interventions | Temozolomide, Cisplatinum |
| Enrollment | 87 |
| Start date | Oct 1, 2003 |
| Primary completion | Jul 1, 2006 |
| Completion | Dec 1, 2007 |
| First posted | Sep 7, 2005 |
| Last update posted | Apr 11, 2012 |
| Countries | France, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: